|
BALTIMORE, MD—February 14, 2013—High-dose methotrexate (MTX) is an important tool for clinicians fighting many types of cancer. Although careful supportive care measures can limit the development of serious toxicities from treatment with high-dose MTX, a small percentage of patients will develop these complications, even with careful use of preventive measures. For these patients, the accumulation of MTX can lead to significant morbidity and mortality.
To improve clinicians' awareness of contemporary evidence and best practices for monitoring and managing methotrexate toxicities, explore emerging evidence for the return to high-dose MTX therapy after resolution of toxicities, and support the application of evidence to practice, Med-IQ, an ACCME-accredited provider of continuing medical education (CME), has developed a certified CME program that explores strategies for preventing and managing the rare but serious toxicities associated with high-dose MTX therapy for cancer.
Preventing and Managing High-Dose Methotrexate Toxicities
This audio-enhanced, CME-certified online publication, designed for oncologists and hematologist/oncologists, discusses key issues and recent noteworthy data on the prevention and management of toxicities associated with the use of high-dose MTX.
“This activity provides clinicians with a focused look at best practices for the prevention of high-dose MTX toxicities and the most up-to-date evidence for the management of these rare but serious toxicities,” said William A. Mencia, MD, CCMEP, Vice President of Education and Medical Affairs at Med-IQ. “For clinicians treating patients with cancer, this activity represents an important opportunity to sharpen their knowledge and ability to apply current evidence for improved prevention and management of high-dose MTX toxicities for patients.”
| Faculty |
| |
Scott C. Howard, MD, MSc
Department of Oncology
Director of Clinical Trials, International Outreach Program
St. Jude Children’s Research Hospital
Memphis, TN
|
|
Interested clinicians are invited to learn more by visiting www.Med-IQ.com\a696
This activity is approved for AMA PRA Category 1 Credit™
Sponsored by Med-IQ.
© 2013 Med-IQ. All rights reserved.
This activity is supported by an educational grant from BTG International.
For more information, call (toll-free) 866 858 7434, e-mail info@med-iq.com, or visit www.Med-IQ.com/a696.
|
About Med-IQ
Med-IQ, America's most respected provider of continuing medical education (CME), inspires healthcare professionals through award-winning activities that deliver sophisticated outcomes-based educational designs with measurable results in professional competence and performance. Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the California Board of Registered Nursing (CBRN), and the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing medical education to physicians, nurses, and pharmacists, respectively.
Med-IQ, a leader in the development of performance improvement (PI) and quality improvement (QI) CME initiatives, has been recognized by the Alliance for Continuing Education in the Health Professions for our excellence in CE research (William Campbell Felch Award 2013, 2011), educational collaborations (2013), outstanding CME outcomes assessment (2012), and exceptional leadership (Leadership Award 2013, President’s Award 2012). To learn more about Med-IQ, visit www.Med-IQ.com, like us on Facebook, follow us on Twitter, and connect with us on LinkedIn.
For more information, contact: |
close
